ResMed Breaks Out As GLP-1 Drugs And Big Tech Help Drive A Quarterly Beat
ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections, shrugging off weight-loss drug worries. Continue reading View comments
- Supported exchanges /
- BE /
- RME.BE
RESMED (RME BE) stock market data APIs
€231.7
0(0%)
as of November 22, 2024
Price chart is built with Anychart
There is no Profile data available for RME.BE.
RESMED Financial Data Overview
| 231.7 | |
| 231.7 | |
| - | |
| 231.7 | |
| 231.7 | |
| 137.3069-237.4513 | |
| 33 727 M | |
| 0 | |
| 0 | |
| 0.008 | |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'RME',
Type:
'Common Stock',
Name:
'RESMED',
Exchange:
'BE',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'June',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Other',
Industry:
'Other',
}
RESMED Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get RESMED Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get RESMED End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get RESMED latest news via APIs
Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics
Analysts on Wall Street project that ResMed (RMD) will announce quarterly earnings of $2.03 per share in its forthcoming report, representing an increase of 23.8% year over year. Revenues are projecte...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
